EMPE Diagnostics AB, founded in 2015 and rooted in innovations from the Karolinska Institute, develops rapid, reliable, and cost-effective diagnostics to address the global tuberculosis (TB) crisis. Its CDSCO-approved product, mfloDx™ MDR-TB, manufactured at an ISO 13485–certified facility in Hyderabad, India, detects Mycobacterium tuberculosis and key drug-resistance mutations. EMPE Diagnostics continues to expand its portfolio, with a Research Use Only (RUO) product launching soon.
